SynthesisFrontiers in oncology2024
Hotspots and future trends of dermatofibrosarcoma protuberans.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dermatofibrosarcoma protuberans misdiagnosed as lipoma: a case report and literature review.Frontiers in oncology · 2026Article
- Beyond COL1A1::PDGFB: Rare fusions and their clinical implications in dermatofibrosarcoma protuberans.World journal of clinical cases · 2025Article
- Dermatofibrosarcoma Protuberans (DFSP): Current Treatments and Clinical Trials.Current treatment options in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Dermatofibrosarcoma protuberans (DFSP) is a moderately malignant soft tissue sarcoma with localized infiltrative growth. The extensive surgical scope and high recurrence rate of DFSP brings dysfunctional, aesthetic, psychological and economic problems to patients. The aim of this study is to explore the global publication characteristics, research hotspots and future trends of DFSP over the past 32 years via an intuitive visualized way. Methods: The Web of Science Core Collection (WoSCC) database was searched for papers related to DFSP published from 1990 to 2022. Then bibliometric analysis of these publications was performed, including collaborative networks, co-citation analysis of journals and references, and cluster analysis of keywords. Results: A total of 1588 papers were retrieved between 1990-2022. The United States was the most prolific country, followed by China. The article Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials, received most citations. Research hotspots and future trends are mainly focused on disease diagnosis, COL1A1-PDGFB fusion gene, drug and surgical treatment, fibrosarcomatous transformation, and immunotherapy. Conclusion: The research on DFSP faces several clinical challenges. This study provides novel insights into future research directions and scientific decisions for DFSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.